ReviewFrontiers in endocrinology2025
Review of nonpharmacological interventions for delaying the effects of cerebral neuropathy caused by diabetes.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Experiences and needs of individuals living with diabetic peripheral neuropathy: a qualitative systematic review and meta-synthesis.Frontiers in neurology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes that affects nearly half of diabetic patients and manifests as chronic pain, sensory loss, and motor dysfunction. The limited efficacy of traditional pharmacological treatments, coupled with their side effects, has intensified the search for alternative therapies that not only mitigate symptoms but also delay the progression of diabetes-related neural complications. In this review, the potential of transcranial magnetic stimulation (TMS) as a nonpharmacological intervention for DPN is explored, with a focus on the ability of TMS to delay neural inflammation-a key factor in the progression of DPN-rather than directly treating diabetes. TMS has shown promising results in alleviating neuropathic pain, promoting nerve regeneration, and regulating autonomic nervous function, making it a strong candidate for delaying adverse neural outcomes. Other neuromodulation techniques, such as spinal cord stimulation (SCS), decompression nerve surgery (DNS), and transcranial direct current stimulation (tDCS), have also been examined for their efficacy in treating DPN. While TMS has significant therapeutic potential for protecting neural function and delaying inflammation, further research is needed to optimize treatment protocols and understand their long-term benefits. This review emphasizes the translational potential of neuromodulation technologies in delaying the progression of diabetes-induced neural damage, underscoring the need for further studies to translate these therapies into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.